Kratom is not a true nootropic. While low doses (1 to 5 grams of dried leaf) produce stimulant-like effects that some users describe as improved focus and alertness, the available research suggests kratom does not enhance cognitive performance and may actually impair it. Its primary pharmacology centers on opioid receptors, not the neurotransmitter pathways that define established cognitive enhancers.
Why People Think of Kratom as a Nootropic
Kratom’s effects are sharply dose-dependent. A few grams of dried leaves produce stimulation and mild euphoria within 5 to 10 minutes, lasting about 2 to 3 hours. At these low doses, users report feeling more alert, motivated, and mentally engaged, which is why kratom shows up in nootropic communities alongside compounds like caffeine or modafinil.
At higher doses, between 10 and 25 grams, the experience flips entirely. The European Union Drugs Agency describes these larger amounts as producing “morphine-like” sedation, calmness, and a dreamlike state lasting up to six hours. This biphasic pattern is one of the clearest signs that kratom operates differently from genuine nootropics, which enhance cognition across their effective dose range rather than switching from stimulation to sedation.
How Kratom Acts on the Brain
The main active compound in kratom, mitragynine, works through multiple receptor systems. Its strongest affinity is for mu-opioid receptors, the same targets that morphine and other opioids activate. Mitragynine also appears to stimulate adrenergic receptors involved in alertness, which likely explains the energizing effect at low doses. A second alkaloid, 7-hydroxymitragynine, binds mu-opioid receptors with roughly 100-fold greater affinity than mitragynine and has been described as more potent than morphine.
Classic nootropics work through entirely different mechanisms. They typically increase the availability of neurotransmitters involved in attention and memory, promote blood flow to the brain, or support long-term nerve cell health. Kratom’s primary action on opioid receptors puts it closer to pain-relieving and mood-altering substances than to cognitive enhancers. The stimulant-like boost at low doses appears to be a secondary effect, not the main pharmacological event.
What the Cognitive Research Shows
When researchers have looked specifically at cognitive performance in kratom users, the findings are not encouraging. A 2024 review published in Behavioural Brain Research concluded that kratom, particularly mitragynine, “may adversely affect cognitive performances.” The proposed explanation is that its alkaloids disrupt synaptic plasticity, the process your brain uses to strengthen connections when learning, along with interfering with proteins essential for transmitting signals between neurons.
This is the opposite of what a nootropic should do. A substance that impairs the brain’s ability to form and reinforce neural connections is working against memory and learning, not supporting them. The subjective feeling of focus that some users experience at low doses does not appear to translate into measurable cognitive improvement. What users may actually be experiencing is a combination of mild euphoria, increased energy, and pain relief that makes it easier to sit down and concentrate, rather than any direct enhancement of mental processing.
Risks That True Nootropics Don’t Carry
One of the defining features of a nootropic, as originally coined by the Romanian psychologist Corneliu Giurgea, is that the substance should have very few side effects and no toxicity. Kratom does not meet this standard. Case reports have documented adverse effects across multiple organ systems, with the brain and liver most commonly affected. Reported neurological effects include seizures and altered mental status, though the mechanism behind kratom-related seizures remains unknown.
The dependency question also separates kratom from nootropics. While mitragynine appears to have relatively low abuse potential in animal studies (rats don’t self-administer it the way they do morphine or methamphetamine), it still acts on opioid receptors, and regular users do develop tolerance and withdrawal symptoms. Kratom has been used traditionally in Southeast Asia to manage opioid withdrawal, which speaks to its opioid-like activity. A substance that produces physical dependence through opioid pathways carries a fundamentally different risk profile than caffeine, L-theanine, or other compounds in the nootropic category.
It’s worth noting that much of the severe harm reported in case studies involves people using kratom alongside other substances. A 2025 review in Frontiers in Pharmacology found insufficient evidence that kratom alone causes severe acute health effects, and emphasized that co-use of other drugs likely increases the risk. Still, the FDA and DEA have warned consumers about liver toxicity, seizures, and death associated with kratom use.
How Regulators View Kratom in 2025
The FDA does not classify kratom as a nootropic, a dietary supplement with approved cognitive claims, or an approved drug of any kind. In 2025, the FDA recommended scheduling 7-hydroxymitragynine (the more potent alkaloid) under the Controlled Substances Act, calling it “a concentrated byproduct of the kratom plant” and “an opioid that can be more potent than morphine.” The agency specifically noted it is not targeting natural kratom leaf products with this action, only concentrated 7-OH products. The DEA is reviewing the recommendation.
Natural kratom leaf remains legal at the federal level in the United States, though several states and municipalities have banned or restricted it. It exists in a regulatory gray area: not approved for any medical use, not scheduled as a controlled substance nationally, and not recognized as a safe dietary ingredient by the FDA.
How Kratom Compares to Established Nootropics
When kratom appears alongside proven cognitive enhancers in academic literature, it’s typically flagged as a substance with “substantial health risks associated with misuse and dependency.” Researchers studying so-called “smart drugs” place kratom in a separate category from compounds with clear evidence of cognitive benefit, noting its primary value lies in pain relief and opioid withdrawal management rather than mental performance.
If you’re looking for cognitive enhancement, the distinction matters. Established nootropics like caffeine have decades of data showing they improve reaction time, attention, and alertness through well-understood mechanisms with a known safety profile. Kratom’s stimulant effects at low doses may feel similar, but they come packaged with opioid receptor activation, a risk of dependence, potential cognitive impairment with regular use, and a safety profile that remains poorly characterized. Calling kratom a nootropic stretches the definition past its breaking point. It’s a psychoactive plant with complex pharmacology that happens to produce stimulation at certain doses, not a cognitive enhancer by any meaningful standard.